Spilimbergo Fernanda Brum, Assmann Taís Silveira, Bellon Marcelo, Hoscheidt Laís Machado, Caurio Cássia Ferreira Braz, Puchalski Márcia, Hochhegger Bruno, Roncato Gabriela, Meyer Gisela Martina Bohns
Centro de Hipertensão Pulmonar, Complexo Hospitalar Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS - Brasil.
Bayer S.A., São Paulo, SP - Brasil.
Arq Bras Cardiol. 2022 May 9;118(6):1059-66. doi: 10.36660/abc.20210492.
Pulmonary hypertension (PH) is a rare and complex disease with poor prognosis, which requires lifelong treatment.
To describe 3-year follow-up real-life data on treatment with soluble guanylate cyclase stimulators (Riociguat) of patients with PH, measuring current risk assessment parameters.
This study retrospectively collected clinical and epidemiological data of patients with PH of group 1 (pulmonary arterial hypertension) and group 4 (chronic thromboembolic PH). Non-invasive and invasive parameters corresponding to the risk assessment were analyzed at baseline and follow-up. Statistical analyses were performed using the SPSS 18.0 software, and p-values < 0.050 were considered statistically significant.
In total, 41 patients receiving riociguat were included in the study. Of them, 31 had already completed 3 years of treatment and were selected for the following analysis. At baseline, 70.7% of patients were in WHO functional class III or IV. After 3 years of treatment, the WHO functional class significantly improved in all patients. In addition, the median of the 6-minute walk test (6MWT) significantly increased from 394 ± 91 m at baseline to 458 ± 100 m after 3 years of follow-up (p= 0.014). The three-year survival rate was 96.7%.
In our real-life cohort, most patients with PH treated with riociguat showed stable or improved risk parameters, especially in the 6MWT, at 3 years of follow-up.
肺动脉高压（PH）是一种罕见且复杂的疾病，预后较差，需要终身治疗。
描述肺动脉高压患者使用可溶性鸟苷酸环化酶刺激剂（利奥西呱）治疗的3年随访真实生活数据，测量当前风险评估参数。
本研究回顾性收集了1组（肺动脉高压）和4组（慢性血栓栓塞性肺动脉高压）肺动脉高压患者的临床和流行病学数据。在基线和随访时分析与风险评估对应的非侵入性和侵入性参数。使用SPSS 18.0软件进行统计分析，p值<0.050被认为具有统计学意义。
共有41例接受利奥西呱治疗的患者纳入研究。其中，31例已完成3年治疗，被选入以下分析。基线时，70.7%的患者处于世界卫生组织功能分级III或IV级。经过3年治疗，所有患者的世界卫生组织功能分级均显著改善。此外，6分钟步行试验（6MWT）的中位数从基线时的394±91米显著增加到随访3年后的458±100米（p = 0.014）。三年生存率为96.7%。
在我们的真实生活队列中，大多数接受利奥西呱治疗的肺动脉高压患者在随访3年时显示风险参数稳定或改善，尤其是在6MWT方面。
